Related Experiment Video
Updated: Dec 20, 2025

siRNA Screening to Identify Ubiquitin and Ubiquitin-like System Regulators of Biological Pathways in Cultured Mammalian Cells
Published on: May 24, 2014
USP37 promotes deubiquitination of HIF2α in kidney cancer
Kai Hong1,2, Lianxin Hu3, Xijuan Liu2
1Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei Province, China.
Abstract:
Clear cell renal cell carcinoma (ccRCC) is characterized by loss of tumor suppressor Von Hippel Lindau (VHL) function, which leads to accumulation of hypoxia inducible factor α (including HIF1α and HIF2α). HIF2α was previously reported to be one of the major oncogenic drivers in ccRCC, however, its therapeutic targets remain challenging. Here we performed a deubiquitinase (DUB) complementary DNA (cDNA) library binding screen and discovered that ubiquitin-specific peptidase 37 (USP37) is a DUB that binds HIF2α and promotes HIF2α deubiquitination. As a result, USP37 promotes HIF2α protein stability in an enzymatically dependent manner, and depletion of USP37 leads to HIF2α down-regulation in ccRCC. Functionally, USP37 depletion causes decreased cell proliferation measured by MTS, two-dimensional (2D) colony formation as well as three-dimensional (3D) anchorage- independent growth. USP37 is also essential for maintaining kidney tumorigenesis in an orthotopic xenograft model and its depletion leads to both decreased primary kidney tumorigenesis and spontaneous lung metastasis. Our results suggest that USP37 is a potential therapeutic target in ccRCC.
Insights
Ubiquitin-specific peptidase 37 (USP37) stabilizes the oncogenic factor HIF2α in clear cell renal cell carcinoma (ccRCC). Inhibiting USP37 reduces tumor growth and metastasis, suggesting USP37 as a potential ccRCC therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Clear cell renal cell carcinoma (ccRCC) is linked to Von Hippel Lindau (VHL) tumor suppressor loss, causing hypoxia-inducible factor α (HIFα) accumulation.
- HIF2α is a key oncogenic driver in ccRCC, but effective therapeutic targets are limited.
Purpose of the Study:
- To identify deubiquitinases (DUBs) that interact with and regulate HIF2α.
- To investigate the role of USP37 in ccRCC pathogenesis and its potential as a therapeutic target.
Main Methods:
- A complementary DNA (cDNA) library screen was used to identify DUBs binding HIF2α.
- USP37's enzymatic activity and effect on HIF2α stability were assessed.
- Cell proliferation assays (MTS, colony formation) and an orthotopic xenograft model were employed.
Main Results:
- USP37 was identified as a DUB that binds and deubiquitinates HIF2α, enhancing its protein stability.
- USP37 depletion led to HIF2α down-regulation and reduced ccRCC cell proliferation and tumor growth.
- Inhibition of USP37 decreased primary kidney tumor formation and lung metastasis in vivo.
Conclusions:
- USP37 promotes ccRCC progression by stabilizing HIF2α.
- USP37 represents a promising therapeutic target for ccRCC treatment.
More Related Videos
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

